• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Orexo (Group)

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. *

 

	Start	1995-01-01 established_pre
	Today	Orexo AB (OMX Nordic List, Mid Cap: ORX)
	Predecessor	Diabact AB
	Industry	drug delivery technology
	Industry 2	diagnostics (medical/biological)
	Person	Sørensen, Nikolaj (Orexo 201110– CCO before Pfizer AB + Boston Consulting Group)
	Person 2	Juuel, Henrik (Orexo 2013Q3– CFO)
	Region	Uppsala
	Country	Sweden
	Street	32A Virdings allé
	City	751 05 Uppsala
	Tel	+46-18-780-8800
	Fax	46-18-780-8888
		Address record changed: 2012-07-22
Basic data	Employees	n. a.
	Currency	SEK
	Cash	91,900,000 (2013-09-30)
		* Document for »About Section«: Orexo AB. (7/14/11). "Press Release: Orexo Takes Leading Position in Diagnostic Breath Tests through Acquisition". Uppsala.
		Record changed: 2014-03-20

Advertisement

More documents for Orexo (Group)

• [1] Orexo AB. (10/23/13). "Press Release: Interim Report January–September 2013"....
• [2] Kibion. (11/23/12). "Press Release: Diabact UBT + IRIS – the Perfect Combination for Helicobacter pylori Diagnosis. Comparison IRIS – Mass Spec"....
• [3] Orexo AB. (3/6/12). "Press Release: Orexo AB Focuses Its Business and Reduces Costs". Uppsala....
• [4] Orexo AB. (10/4/11). "Press Release: Orexo Appoints Peter Edman as Chief Scientific Officer". Uppsala....
• [5] Orexo AB. (9/16/11). "Press Release: Orexo Strengthens Its Commercial Knowhow and Appoints Nikolaj Sørensen as Chief Commercial Officer". Uppsala....
• [6] Orexo AB. (8/31/11). "Press Release: Orexo Appoints Carl-Johan Blomberg as New Chief Financial Officer". Uppsala....
• [7] Orexo AB. (7/14/11). "Press Release: Orexo Takes Leading Position in Diagnostic Breath Tests through Acquisition". Uppsala....
• [8] Orexo AB. (1/13/11). "Press Release: Anders Lundström to Be the New CEO of Orexo". Uppsala....
• [9] Boehringer Ingelheim. (12/16/10). "Press Release: Boehringer Ingelheim and Orexo Report Progress in Their Pain and Inflammatory Diseases Collaboration". Uppsala & Ingelheim....
• [10] Orexo AB. (10/27/10). "Press Release: Orexo Strengthens Its Subsidiary Kibion by Recruiting Petter Bäckgren as CEO". Uppsala....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2013. Made in Germany.